Reuters logo
BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313
2017年9月19日 / 上午11点24分 / 1 个月前

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

Sept 19 (Reuters) - ProQR Therapeutics NV

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

* ProQR Therapeutics NV - first-in-human clinical trial of QR-313 will be initiated in 2018

* ProQR Therapeutics NV - clinical data from QR-313 program will also be available in 2018 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below